Kalvista Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Kalvista Pharmaceuticals Inc (KALV) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Kalvista Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 13M vs 266,556M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+1,188.0% annualized vs trailing 12 months), vs decelerating (-3.5%) for its tracked peer group.
- Profitability: Its -57.5% net margin compares with 19.4% for the peer group.
- Peer revenue share: Kalvista Pharmaceuticals Inc accounted for 0.1% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.28M compares with $1.12M for the peer group (0.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
KALV Sales vs. its Competitors, Q1 2026
With a net margin of -57.48 %, Kalvista Pharmaceuticals Inc reported lower profitability than its competitors (19.36 %).
Kalvista Pharmaceuticals Inc generated 0.06 % of the combined sales of its peer group.
Kalvista Pharmaceuticals Inc vs. its Competitors, Q1 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Kalvista Pharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Kalvista Pharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Kalvista Pharmaceuticals Inc's competitor groups requires a Commercial License.
Kalvista Pharmaceuticals Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Kalvista Pharmaceuticals Inc | - | - | - | No |
| Competitors combined (74) | ||||
| High-Confidence Competitors (8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
KALV Stock Performance relative to its Competitors
KALV Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Regulus Therapeutics Inc | 282.9% | Outperformed |
| 2 | Tango Therapeutics Inc | 282.9% | Outperformed |
| 3 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 4 | Edgewise Therapeutics inc | 282.9% | Outperformed |
| 5 | Apellis Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Kalvista Pharmaceuticals Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Kalvista Pharmaceuticals Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Kalvista Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Kalvista Pharmaceuticals Inc | 1,473.75 | 12.69 |
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Beone Medicines Ltd | 552,467.82 | 6,128.24 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Vertex Pharmaceuticals Inc | 134,661.38 | 12,587.20 |
| Bristol myers Squibb Company | 130,826.24 | 49,186.00 |
| SUBTOTAL | 2,440,798.03 | 276,554.97 |
Sign in to see all competitors of Kalvista Pharmaceuticals Inc .
Sources: Kalvista Pharmaceuticals Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Kalvista Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Kalvista Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Allergan plc | Named by the company | 85% |
| Novartis International AG | Named by the company | 85% |
| Roche Holding AG | Named by the company | 85% |
| Alimera Sciences, Inc. | Named by the company | 85% |
| Boehringer Ingelheim | Named by the company | 85% |
| Pharvaris | Named by the company | 85% |
| Attune Pharmaceuticals, Inc. | Named by the company | 85% |
| Ohr Pharmaceutical, Inc. | Named by the company | 85% |
| Intellia Therapeutics Inc | Named by the company | 85% |
| Allegro Ophthalmics, LLC | Named by the company | 85% |
| GlaxoSmithKline plc | Named by the company | 85% |
| Regeneron Pharmaceuticals | Named by the company | 85% |
| Aerpio Therapeutics | Named by the company | 85% |
| BioCryst Pharmaceuticals, Inc. | Named by the company | 85% |
| Oxurion NV | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Kalvista Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Kalvista Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
| Viatris Inc | Developed Markets 57.61 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Kalvista Pharmaceuticals Inc .
Kalvista Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Kalvista Pharmaceuticals Inc | 1,474 | 282,000 | -4,117,533 |
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Beone Medicines Ltd | 552,468 | 510,686 | 54,642 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Vertex Pharmaceuticals Inc | 134,661 | 31,079,506 | 10,877,037 |
| Bristol myers Squibb Company | 130,826 | 1,513,415 | 285,354 |
| PEERS TOTAL | 2,439,324 | 1,118,328 | 200,119 |
Sign in to see all peers for Kalvista Pharmaceuticals Inc .
Kalvista Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Beone Medicines Ltd | United States 51.69 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Kalvista Pharmaceuticals Inc .
Kalvista Pharmaceuticals Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Kalvista Pharmaceuticals Inc's industry classification, broader than the peer set above. Market cap in millions of $.Kalvista Pharmaceuticals Inc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Kalvista Pharmaceuticals Inc | 1,474 | 0.00 % |
Market cap and industry share for the rest of Kalvista Pharmaceuticals Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-06-12.
Kalvista Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 29.0x | 4.5x | +24.6x |
| Return on Equity | -555.06 % | industry aggregate | -571.96 % |
| Return on Invested Capital | -75.62 % | -2.95 % (avg) | -72.67 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Kalvista Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | 500.00 % | 445.67 % | -34.63 % | - | - | - | - |
| Operating Margin | -230.46 % | -119.35 % | -363.22 % | - | - | - | - |
| Return on Invested Capital | -12.20 % | -15.47 % | -21.77 % | -34.42 % | -18.47 % | -47.88 % | -49.71 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Kalvista Pharmaceuticals Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Kalvista Pharmaceuticals Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Kalvista Pharmaceuticals Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Kalvista Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+1,188.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 572.0 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (30.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-3.5% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Kalvista Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Kalvista Pharmaceuticals Inc | 3.76 | 5.74 | 2.09 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
Sign in to see all peers for Kalvista Pharmaceuticals Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Kalvista Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Kalvista Pharmaceuticals Inc | Q1 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| PEERS TOTAL | +18.8 % | +37.2 % |
Sign in to see all peers for Kalvista Pharmaceuticals Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Kalvista Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Kalvista Pharmaceuticals Inc | Q1 2026 | - | -58.2 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
Sign in to see all peers for Kalvista Pharmaceuticals Inc .
Kalvista Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Kalvista Pharmaceuticals Inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
Sign in to see all peers for Kalvista Pharmaceuticals Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Kalvista Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Kalvista Pharmaceuticals Inc | - | 116.13 |
| Eli Lilly And Company | 39.77 | 13.29 |
| Beone Medicines Ltd | 834.09 | 90.15 |
| Amgen Inc | 25.97 | 5.97 |
| Vertex Pharmaceuticals Inc | 30.77 | 10.70 |
| Bristol myers Squibb Company | 14.06 | 2.66 |
| PEERS AVERAGE | 49.51 | 8.83 |
Sign in to see all peers for Kalvista Pharmaceuticals Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.